As of November 6, 2026, Kymera Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 8, 2026 to July 27, 2026, naming 1 departure. The latest filing names Jared Gollob, leaving (Form 8-K, July 27, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Kymera Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Kymera Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-08 to 2026-07-27. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Kymera Therapeutics, Inc. files it.
Also on the record for Kymera Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 6.6% of the class | 5%+ stakes | Source |
| September 8, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 10.7% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 8.6% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Atlas Venture Fund X, L.P. | 2.9% of the class | 5%+ stakes | Source |
| June 26, 2026 | Stake report, Schedule 13D/A, by BIOTECHNOLOGY VALUE FUND L P | 6.3% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by T. Rowe Price Investment Management, Inc. | 6.7% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 4.8% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 14.3% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 5.5% of the class | 5%+ stakes | Source |
| January 8, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 11.2% of the class | 5%+ stakes | Source |
| December 15, 2025 | Stake report, Schedule 13D/A, by BIOTECHNOLOGY VALUE FUND L P | 8.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Kymera Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Kymera Therapeutics, Inc. and the records around it.
Kymera Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Atlas Venture Fund X, L.P. also filed stake reports on 5 other companies: Obsidian Therapeutics, Inc. (Aug 2026), Q32 Bio Inc. (May 2026), GENERATION BIO CO. (May 2026)
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
Watch Kymera Therapeutics, Inc.
Get an email when Kymera Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Kymera Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Kymera Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kymera Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 17 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-27 | Out | 8-K, 2026-07-27 | |||
| 2026-06-08 | Reported | not named in the filing | 8-K, 2026-06-08 |
New leaders reset buying decisions — get the Full Report on Kymera Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Kymera Therapeutics, Inc., with the record behind each one.
Find candidates like senior executive at Kymera Therapeutics, Inc.Every change, in the filing's words
Departing: Jared Gollob
Dr. Gollob informed the Company that he resigned as CMO for personal reasons, and not as the result of any disagreement with the Company's practices or policies.
- Jared Gollob, M.D., communicated his intention to retire from his role as Chief Medical Officer ("CMO") of Kymera Therapeutics, Inc. (the "Company") and submitted his resignation on July 27, 2026.
- Dr. Gollob will continue providing services to the Company as an advisor until December 31, 2026.
- Effective July 27, 2026, Terence Rooney, M.D., will succeed Dr. Gollob as CMO of the Company.
Reported
Jeremy Chadwick communicated his intention to retire and submitted his resignation as Chief Operating Officer ("COO") on June 5, 2026.
- Mr. Chadwick will remain an employee of Kymera Therapeutics, Inc. (the "Company") as an advisor until November 2026.
- Mr. Chadwick informed the Company that he resigned as COO for personal reasons, and not as the result of any disagreement with the Company's practices or policies.
Tools for this story
Each opens in a new tab, filled in for Kymera Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.